Immuneering Corp
IMRX$101M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCAMBRIDGE
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
This month
Market Overview
Stock performance and key metrics
IMRX News
Catalyst Timeline
1 upcoming, 0 past
Phase 2Next
IMM-1-104 Monotherapy (Treatment Group A) Phase 2 Est. Readout
June 2026~EstimatedIMM-1-104 Monotherapy (Treatment Group A)209
Primary completion for IMM-1-104 Monotherapy (Treatment Group A) trial (NCT05585320) in Advanced Solid Tumor
SourceDrug Pipeline
Atebimetinib
Pancreatic Cancer
IMM-1-104 Monotherapy (Treatment Group A)
Advanced Solid Tumor
IMM-6-415
Advanced Solid Tumor (Phase 1)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Atebimetinib | Phase 3 | Pancreatic Cancer | - | - |
IMM-1-104 Monotherapy (Treatment Group A) | Phase 2 | Advanced Solid Tumor | - | - |
IMM-6-415 | Phase 2 | Advanced Solid Tumor (Phase 1) | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply